The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 18, 2020

Filed:

Mar. 16, 2017
Applicant:

The Regents of the University of California, Oakland, CA (US);

Inventors:

Roger S. Lo, Los Angeles, CA (US);

Willy Hugo, Los Angeles, CA (US);

Antoni Ribas, Los Angeles, CA (US);

Jesse Zaretsky, Santa Monica, CA (US);

Assignee:
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
G01N 31/00 (2006.01); A61K 31/385 (2006.01); C12Q 1/6886 (2018.01); C07K 16/28 (2006.01); G16B 20/00 (2019.01); A61P 35/00 (2006.01); G16B 5/00 (2019.01); G16B 25/00 (2019.01); A61K 31/337 (2006.01); A61K 31/427 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); C12Q 1/686 (2018.01); G16B 25/10 (2019.01);
U.S. Cl.
CPC ...
A61K 31/385 (2013.01); A61K 31/337 (2013.01); A61K 31/427 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01); C07K 16/2818 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6886 (2013.01); G16B 5/00 (2019.02); G16B 20/00 (2019.02); G16B 25/00 (2019.02); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); G16B 25/10 (2019.02);
Abstract

Methods of predicting or detecting sensitivity to therapeutic effects of anti-PD-1 therapy in a patient suffering from melanoma, as well as for selecting somatic mutanomes and transcriptomes of melanoma biopsies. A tumor sample obtained from the patient is assayed for a measure of anti-PD-1 therapy sensitivity via, for example, whole transcriptome sequencing, antibody based protein quantifications, mass spectrometry based protein quantification, targeted mRNA sequencing, real-time RT-PCR, Sanger sequencing, targeted sequencing and/or whole exome/genome sequencing. Samples are selected that exhibit a higher first enrichment similarity score and/or a lower second enrichment similarity score, and/or at least one measure of sensitivity. A patient whose sample was selected herein as a candidate for anti-PD-1 therapy is thereby identified. The method of the invention can further comprise treating the patient with anti-PD-1 therapy, optionally in conjunction with combinatorial therapy.


Find Patent Forward Citations

Loading…